3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Conditions
Motor Activity
32
Breast Neoplasms
21
Neoplasms
16
Prostatic Neoplasms
11
Obesity
8
Sarcopenia
6
Colorectal Neoplasms
6
Pancreatic Neoplasms
5
Lung Neoplasms
5
Head and Neck Neoplasms
5
Polycystic Ovary Syndrome
4
Signs and Symptoms
3
Multiple Myeloma
3
Lymphedema
3
Inflammation
3
Fatigue
3
Diabetes Mellitus, Type 2
3
Colonic Neoplasms
3
Brain Neoplasms
3
Uterine Cervical Neoplasms
2
Pharyngeal Neoplasms
2
Overweight
2
Osteoporosis, Postmenopausal
2
Osteoporosis
2
Lymphoma
2
Leukemia, Myeloid, Acute
2
Leukemia
2
Laryngeal Neoplasms
2
Insulin Resistance
2
Hematopoietic and Lymphatic System Neoplasm
2
Interventions
Cyclophosphamide
62
fludarabine phosphate
55
Peripheral Blood Stem Cell Transplantation
44
Tacrolimus
41
Busulfan
40
ruxolitinib
39
Mycophenolic Acid
36
Whole-Body Irradiation
32
Antilymphocyte Serum
29
Methotrexate
27
Cyclosporine
27
fludarabine
24
Melphalan
19
Filgrastim
19
Radiotherapy
15
Methylprednisolone
13
thymoglobulin
12
Etoposide
12
Cord Blood Stem Cell Transplantation
12
Azacitidine
12
Stem Cell Transplantation
11
Sirolimus
11
11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene
10
Decitabine
9
Specimen Handling
8
Prednisone
8
Cytarabine
8
Imatinib Mesylate
7
Granulocyte Colony-Stimulating Factor
7
Flow Cytometry
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Primary Myelofibrosis
×
Resistance Training
×
Clear all
NCT07518940
2026-04-09
ENERGIA
University of Turin, Italy
Phase NA
Not yet recruiting
25 enrolled